PDF factsheet
      Z

antiplatelets drug in percutaneous coronary intervention for all type of patients, clinical trials results

12 months dual antiplatelet versus 6 months dual antiplatelet
ISAR-SAFE, 2009
NCT00661206
additional 6 month period of clopidogrel
versus
placebo
Patients on clopidogrel therapy at least 6 months after DES implantation, who do not require a reintervention double blind
Follow-up duration: 12 months
24 months of dual antiplatelet treatment versus 6 months dual antiplatelet
PRODIGY, 2011
NCT00611286
24 months of dual antiplatelet treatment (clopidogrel plus aspirin)
versus
6 months of dual antiplatelet treatment (clopidogrel plus aspirin)
patients (74 with acute coronary syndromes and 26 with stable angina) who underwent stentingopen
Follow-up duration: 2 years
3 months DAPT versus 12 months DAPT
OPTIMIZE, 2013
NCT01113372
3 months DAPT (aspirin (100-200 mg daily) and clopidogrel (75 mg daily))
versus
12 months DAPT
patients with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stentsopen-label
Brazil
6-month dual antiplatelet therapy versus 12 months dual antiplatelet
EXCELLENT, 2011
NCT00698607
dual antiplatelet therapy for six months
versus
dual antiplatelet therapy for one year
patients with coronary artery disease
cilostazol versus aspirin
Kunishima, 1997
Cilostazol 200 mg qD unspecified durationg qD
versus
Aspirin 81 mg qD
cilostazol + aspirin versus aspirin
Sekiya, 1998
Cilostazol 200 mg qD x6mos Aspirin 81 mg qD
versus
Coumadin unspecified regimen Aspirin 81 mg qD
cilostazol + aspirin versus ticlopidine + aspirin
Kozuma, 2001
Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD
versus
Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD
Ochiai, 1999
Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID
versus
Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID
Park, 1999
Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD
versus
Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD
Yoon, 1999
Cilostazol 100 mg BID x30 days Aspirin 100 mg qD
versus
Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD
Kamishirado, 2002
Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD
versus
Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD
clopidogrel + aspirin versus ticlopidine + aspirin
Müller, 2000
Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD
versus
Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD
CLASSICS, 2000
Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·`
versus
Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD
TOPPS, 2001
Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD
versus
Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD
Piamsomboon, 2001
Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD
versus
Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD
clopidogrel+aspirin versus aspirin
REAL-LATE, ZEST-LATE, 2010
NCT00484926
clopidogrel plus aspirin
versus
aspirin alone
patients who had received drugeluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 monthsopen
Follow-up duration: 19.2 months
South Korea
Endeavor stent and three months of DAPT versus standard 12-month DAPT and other DES
RESET,
NCT01145079

versus
high-dose clopidogrel versus normal-dose clopidogrel
GRAVITAS, 2011
NCT00645918
High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter)
versus
regular clopidogrel dose
patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)open
Follow-up duration: 6 months
North America
prolonged dual antiplatelet therapy versus 12 months dual antiplatelet
DES-LATE, 2010
NCT00484926
dual antiplatelet therapy (clopidogrel plus aspirin)
versus
aspirin alone
patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 monthsopen
Follow-up duration: 19.2 mo
South Korea
ticlopidine + aspirin versus aspirin
STARS (vs aspirin), 1998
Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj
versus
Aspirin 325 mg qD
Hall, 1996
Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days
versus
Aspirin 325 mg qD
ticlopidine + aspirin versus coumadin + aspirin
STARS (vs coumadin+asp), 1998
Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD
versus
Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID
FANTASTIC, 1998
Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD
versus
Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj
ISAR, 1996
Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj
versus
Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID
MATTIS, 1998
Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD
versus
Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj
Foussas, 2000
Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD
versus
Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID
triple antiplatelet versus dual antiplatelet therapy
CILON-T, 2010
triple antiplatelet therapy with aspirin, clopidogrel, and cilostazol for 6 month
versus
dual antiplatelet therapy
real-world patients undergoing PCI
Follow-up duration: 6 mo
triple therapy versus dual antiplatelet therapy
WOEST,
NCT00769938
oral anticoagulants, aspirin and clopidogrel
versus
oral anticoagulants, clopidogrel

  Options


in first

in second

  Filter